Skip to main content

Table 2 Clinical characteristics and outcome

From: Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls

  Overall
(N = 10)
Stable disease
(N = 4)
Progressive disease
(N = 6)
Uptake Grade ≥ 3 7/10 (70%) 4/4 (100%) 3/6 (50%)
Uptake Grade < 3 3/10 (30%) 0/0 (0%) 3/6 (50%)
SSTR2a tumour expression 4/10 (40%) 4/4 (100%) 0/6 (0%)
Loss of correlation CT 3/6 (50%) 0/4 (0%) 3/6 (50%)
  1. Abbreviations: Calcitonin, CT; Grade 3: uptake > normal liver uptake; N, number; SSTR, somatostatin receptor